Once-daily netarsudil generally safe, with minimal treatment-related adverse events

Inder Paul Singh
WASHINGTON — Once-daily netarsudil for patients with ocular hypertension or open-angle glaucoma was safe, with mild conjunctival hyperemia being the most frequently occurring ocular adverse event, according to a speaker here.
In a pooled analysis of four phase 3 trials comparing once-daily Rhopressa (netarsudil ophthalmic solution 0.02%, Aerie Pharmaceuticals) with twice-daily timolol, netarsudil had limited ocular adverse events and effects on heart rate change from baseline and was “generally safe and well tolerated,” Inder Paul Singh, MD, said at the

Full Story →